International Research in Chinese Medicine

Objective To explore the clinical efficacy of Linggui Zhugan Decoction combined with Shakubatryl valsartana in the treatment of left ventricular ejection fraction preserving heart failure. Methods From January to December 2023, patients with heart failure with left ventricular ejection fraction preservation were selected as the study objects. 100 patients were randomly selected and divided into control group and observation group according to simple randomization method, with 50 patients in each group. The control group was treated with sakubactril and valsartana, and the observation group was treated with Linggui Zhugan Decoction on the basis of the control group. Serum inflammatory factors, cardiac parameters and cardiac function indexes were compared between the two groups before and after treatment. Results Before treatment, there were no significant differences in serum inflammatory factors, cardiac function indexes and cardiac parameters in patients with left ventricular ejection fraction preservation heart failure between the two groups: P > 0.05; After treatment, the improvement of serum inflammatory factors, cardiac function indexes and cardiac parameters in the observation group was better than that in the control group, with statistical significance (P < 0.05). Conclusion Linggui Zhugan Decoction combined with Shakubatryl valsartan sodium tablets can significantly improve the cardiac function indexes and improve the cardiac dysfunction in patients with left ventricular ejection fraction preservation heart failure.

Sweet decoction; Shakubatrivalsartan sodium; Left ventricular ejection fraction; Heart failure; Clinical efficacy